Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

SARS-CoV-2 infects cells lining the blood-retinal barrier and induces a hyperinflammatory immune response in the retina via systemic exposure.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101238921 Publication Model: eCollection Cited Medium: Internet ISSN: 1553-7374 (Electronic) Linking ISSN: 15537366 NLM ISO Abbreviation: PLoS Pathog Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science, c2005-
    • Subject Terms:
    • Abstract:
      SARS-CoV-2 has been shown to cause wide-ranging ocular abnormalities and vision impairment in COVID-19 patients. However, there is limited understanding of SARS-CoV-2 in ocular transmission, tropism, and associated pathologies. The presence of viral RNA in corneal/conjunctival tissue and tears, along with the evidence of viral entry receptors on the ocular surface, has led to speculation that the eye may serve as a potential route of SARS-CoV-2 transmission. Here, we investigated the interaction of SARS-CoV-2 with cells lining the blood-retinal barrier (BRB) and the role of the eye in its transmission and tropism. The results from our study suggest that SARS-CoV-2 ocular exposure does not cause lung infection and moribund illness in K18-hACE2 mice despite the extended presence of viral remnants in various ocular tissues. In contrast, intranasal exposure not only resulted in SARS-CoV-2 spike (S) protein presence in different ocular tissues but also induces a hyperinflammatory immune response in the retina. Additionally, the long-term exposure to viral S-protein caused microaneurysm, retinal pigmented epithelium (RPE) mottling, retinal atrophy, and vein occlusion in mouse eyes. Notably, cells lining the BRB, the outer barrier, RPE, and the inner barrier, retinal vascular endothelium, were highly permissive to SARS-CoV-2 replication. Unexpectedly, primary human corneal epithelial cells were comparatively resistant to SARS-CoV-2 infection. The cells lining the BRB showed induced expression of viral entry receptors and increased susceptibility towards SARS-CoV-2-induced cell death. Furthermore, hyperglycemic conditions enhanced the viral entry receptor expression, infectivity, and susceptibility of SARS-CoV-2-induced cell death in the BRB cells, confirming the reported heightened pathological manifestations in comorbid populations. Collectively, our study provides the first evidence of SARS-CoV-2 ocular tropism via cells lining the BRB and that the virus can infect the retina via systemic permeation and induce retinal inflammation.
      Competing Interests: The authors have declared that no competing interests exist.
      (Copyright: © 2024 Monu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
    • References:
      Ophthalmology. 2020 Jul;127(7):977-979. (PMID: 32291098)
      Ocul Surf. 2006 Oct;4(4):178-87. (PMID: 17146573)
      Annu Rev Med. 2022 Jan 27;73:129-147. (PMID: 34379444)
      Front Immunol. 2021 Jul 28;12:701295. (PMID: 34394095)
      Cells. 2021 Apr 02;10(4):. (PMID: 33918318)
      Ocul Surf. 2021 Jan;19:190-200. (PMID: 32502616)
      Cureus. 2023 Apr 12;15(4):e37487. (PMID: 37187644)
      Nat Methods. 2022 Apr;19(4):392-394. (PMID: 35396468)
      SSRN. 2020 Jul 15;:3650574. (PMID: 32742243)
      PLoS Pathog. 2012;8(3):e1002569. (PMID: 22396651)
      Am J Ophthalmol Case Rep. 2023 Jun 29;32:101876. (PMID: 37425218)
      Nat Immunol. 2020 Nov;21(11):1327-1335. (PMID: 32839612)
      mBio. 2022 Jan 18;13(1):e0343621. (PMID: 35038898)
      F1000Res. 2022 Sep 16;11:1059. (PMID: 37012994)
      Cell Stem Cell. 2021 Jul 1;28(7):1205-1220.e7. (PMID: 34022129)
      Proc Natl Acad Sci U S A. 2023 May 23;120(21):e2217119120. (PMID: 37186819)
      PLoS Biol. 2021 Nov 4;19(11):e3001284. (PMID: 34735434)
      EClinicalMedicine. 2020 Oct;27:100550. (PMID: 32984785)
      Virol J. 2022 May 26;19(1):92. (PMID: 35619180)
      Int Med Case Rep J. 2021 Jun 23;14:421-427. (PMID: 34188557)
      J Aging Sci. 2021;Vol 9(Suppl 7):. (PMID: 34765681)
      J Ophthalmic Inflamm Infect. 2022 Dec 20;12(1):42. (PMID: 36538113)
      mSphere. 2019 May 8;4(3):. (PMID: 31068433)
      Ther Adv Ophthalmol. 2023 Mar 14;15:25158414221149916. (PMID: 36938488)
      Indian J Ophthalmol. 2023 Feb;71(2):660-662. (PMID: 36727383)
      Indian J Ophthalmol. 2021 Dec;69(12):3633-3636. (PMID: 34827010)
      J Ophthalmic Vis Res. 2021 Jan 20;16(1):103-112. (PMID: 33520133)
      Clin Microbiol Rev. 2023 Dec 20;36(4):e0005723. (PMID: 37966199)
      JAMA Psychiatry. 2021 Jun 1;78(6):682-683. (PMID: 33769431)
      Int Health. 2022 Mar 2;14(2):113-121. (PMID: 34043796)
      Graefes Arch Clin Exp Ophthalmol. 2023 Jul;261(7):1793-1808. (PMID: 36598554)
      JCI Insight. 2017 Feb 23;2(4):e92340. (PMID: 28239662)
      Clin Vaccine Immunol. 2010 Mar;17(3):342-53. (PMID: 20089796)
      Am J Ophthalmol. 2021 Oct;230:151-155. (PMID: 34022227)
      J Clin Med. 2022 Nov 24;11(23):. (PMID: 36498504)
      Brain Behav Immun. 2023 Mar;109:251-268. (PMID: 36682515)
      Viruses. 2018 Sep 28;10(10):. (PMID: 30274199)
      Eur J Ophthalmol. 2023 Jul;33(4):NP42-NP45. (PMID: 35815850)
      Int Ophthalmol. 2022 Jan;42(1):323-336. (PMID: 34379290)
      N Engl J Med. 2015 Jun 18;372(25):2423-7. (PMID: 25950269)
      Ocul Surf. 2020 Oct;18(4):537-544. (PMID: 32544566)
      Ocul Surf. 2022 Jan;23:184-194. (PMID: 34583089)
      Emerg Microbes Infect. 2018 May 25;7(1):96. (PMID: 29802245)
      Front Med (Lausanne). 2022 Jan 13;8:758414. (PMID: 35096863)
      Nat Commun. 2021 Dec 7;12(1):7092. (PMID: 34876592)
      Vacunas. 2021 Jan-Apr;22(1):56-57. (PMID: 33013257)
      Signal Transduct Target Ther. 2023 Sep 20;8(1):357. (PMID: 37726282)
      Cell Rep. 2016 Sep 20;16(12):3208-3218. (PMID: 27612415)
      Trop Med Infect Dis. 2022 Jun 15;7(6):. (PMID: 35736984)
      Eye (Lond). 2021 Apr;35(4):1117-1139. (PMID: 33514902)
      J Immunol. 2020 Apr 1;204(7):1810-1824. (PMID: 32086387)
      J Virol. 2022 Jan 12;96(1):e0096421. (PMID: 34668775)
      Nat Commun. 2022 Dec 12;13(1):7675. (PMID: 36509737)
      Invest Ophthalmol Vis Sci. 2014 Oct 21;55(11):7321-31. (PMID: 25335984)
      Front Med (Lausanne). 2022 Sep 13;9:877023. (PMID: 36177323)
      Curr Ophthalmol Rep. 2021;9(3):77-82. (PMID: 34377601)
      Ocul Surf. 2019 Jul;17(3):551-559. (PMID: 30905842)
      Stem Cell Reports. 2022 Apr 12;17(4):789-803. (PMID: 35334213)
      Trends Microbiol. 2021 Mar;29(3):224-237. (PMID: 33451855)
      Indian J Ophthalmol. 2023 Feb;71(2):663-666. (PMID: 36727384)
      Curr Opin Ophthalmol. 2017 Nov;28(6):600-606. (PMID: 28872492)
      Dev Cell. 2021 Feb 22;56(4):427-442.e5. (PMID: 33422265)
      Cell. 2020 Apr 16;181(2):271-280.e8. (PMID: 32142651)
      Rom J Ophthalmol. 2022 Oct-Dec;66(4):289-298. (PMID: 36589322)
      Mol Cell Biochem. 2022 Mar;477(3):849-864. (PMID: 35066705)
      Cureus. 2023 Jun 20;15(6):e40695. (PMID: 37485114)
      PLoS Pathog. 2023 Jan 18;19(1):e1011077. (PMID: 36652443)
    • Grant Information:
      R01 EY032495 United States EY NEI NIH HHS
    • Accession Number:
      EC 3.4.17.23 (Angiotensin-Converting Enzyme 2)
      0 (Spike Glycoprotein, Coronavirus)
      0 (spike protein, SARS-CoV-2)
      EC 3.4.17.23 (Ace2 protein, mouse)
    • Publication Date:
      Date Created: 20240410 Date Completed: 20240423 Latest Revision: 20240425
    • Publication Date:
      20240425
    • Accession Number:
      PMC11034659
    • Accession Number:
      10.1371/journal.ppat.1012156
    • Accession Number:
      38598560